Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healwell AIHWAIF +0.62%59 3-Year EBITDA Growth Rate is 42.40% as of Jun. 2026, which is 99% above its 10-year median of 21.30. GuruFocus rates HWAIF with a GF Score™ of 59/100 and a GF Value™ of $2.32 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Healwell AI ranks better than 87.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Healwell AI was 42.40% per year. The lowest was -15.40% per year. And the median was 21.30% per year.
Healwell AI (OTCPK:HWAIF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Healwell AI 3-Year EBITDA Growth Rate Related Terms
HWAIF vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Healwell AI's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healwell AI 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healwell AI's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Healwell AI's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.40% mean?
Healwell AI (HWAIF) has a 3-Year EBITDA Growth Rate of 42.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healwell AI and its competitors. This is 99% above median its historical median of 21.30. According to the industry distribution chart, Healwell AI ranks #68 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 12.9%.
Is Healwell AI's 3-Year EBITDA Growth Rate too high?
Healwell AI's current 3-Year EBITDA Growth Rate of 42.40% is 99% above median its 10-year median of 21.30. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Healwell AI's value of 42.40% is 315.7% above this industry median. Based on the distribution chart, Healwell AI ranks #68 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Healwell AI has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healwell AI's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Healwell AI ranks #68 out of 526 companies for 3-Year EBITDA Growth Rate. This places Healwell AI in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.20. Healwell AI's value of 42.40% is 315.7% above this benchmark. While the company's 10-year median is 21.30 vs. the industry median of 10.20, Healwell AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healwell AI's current 3-Year EBITDA Growth Rate of 42.40% is 315.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healwell AI and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healwell AI's current 3-Year EBITDA Growth Rate is 42.40%, which is 99% above median its own 10-year median of 21.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healwell AI stock overvalued right now?
Based on GuruFocus' analysis, Healwell AI (HWAIF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.32, compared to a current price of $0.57 — trading 75.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 42.40%, which is 99% above median its 10-year median of 21.30 and 315.7% above the Healthcare Providers & Services industry median of 10.20. Healwell AI's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Healwell AI (HWAIF), the current 3-Year EBITDA Growth Rate is 42.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healwell AI (HWAIF) Overvalued in 2026?
Based on GuruFocus' analysis, Healwell AI stock appears to be undervalued.
The current stock price of $0.57 is trading 75.4% below its estimated GF Value™ of $2.32.
GuruFocus considers Healwell AI to be Possible Value Trap.
Key valuation signals for HWAIF:
3-Year EBITDA Growth Rate: 42.40% (99% above median its 10-year median of 21.30)
GF Value™: $2.32 vs. price of $0.57 (75.4% below fair value)
Industry Position: 315.7% above the Healthcare Providers & Services median (#68 of 526)
No single metric tells the full story. See the HWAIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healwell AI Inc is a Canadian healthcare technology company. It operates in two reportable segments: Al and Data Sciences, and Healthcare Software. The majority of Healwell's revenue is generated from the Healthcare Software segment, whose core software suite consists of Electronic Health Records (EHR), Digital Front Door (DFD), and Digital Care Records (DCR). These products consolidate diverse data sources, helping physicians get a comprehensive view of individual patient health. The AI and Data Sciences division offers AI technologies and algorithms that screen clinical information and patient records, and aid in identifying patients at high risk for specific conditions. Geographically, the company generates maximum revenue from Australia and New Zealand, and the rest from Canada.
59GF Score
Get the complete analysis for HWAIF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HWAIF has been successfully added to your 
